Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 5.6% - Time to Sell?

Key Points

• Cullinan Therapeutics shares fell about 5.6% intraday to roughly $14.49 with only ~114,000 shares trading (an ~85% drop vs. its average daily volume), and the stock is trading near its 50‑day ($14.22) and 200‑day ($11.70) moving averages.
• Analyst coverage is mixed but leans positive—eight Buys, one Hold and one Sell—giving a MarketBeat consensus of "Moderate Buy" with an average price target of $29.89 (individual targets range into the $30s).
• Insiders have been selling (78,492 shares worth ~$1.11M in the last three months) while the company reports negative earnings (quarterly EPS -$0.77; trailing P/E -4.26) and maintains a ~$875.5M market cap; Cullinan remains a clinical‑stage biotech with lead programs including CLN‑619 and CLN‑049.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report)'s share price was down 5.6% during mid-day trading on Tuesday . The stock traded as low as $14.96 and last traded at $14.4850. Approximately 114,042 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 772,278 shares. The stock had previously closed at $15.34.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. BTIG Research reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Cullinan Therapeutics in a research note on Monday. Wall Street Zen lowered shares of Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, February 8th. Guggenheim assumed coverage on shares of Cullinan Therapeutics in a research note on Monday, February 2nd. They issued a "buy" rating and a $30.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Friday, April 10th. Finally, Citigroup assumed coverage on shares of Cullinan Therapeutics in a research note on Tuesday, February 17th. They issued a "buy" rating and a $33.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $29.89.

Cullinan Therapeutics Stock Down 7.1%

The firm has a market capitalization of $875.54 million, a price-to-earnings ratio of -4.26 and a beta of -0.09. The stock's 50 day moving average price is $14.22 and its two-hundred day moving average price is $11.70.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.03. On average, equities analysts expect that Cullinan Therapeutics, Inc. will post -3.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Nadim Ahmed sold 16,381 shares of the company's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $13.62, for a total value of $223,109.22. Following the transaction, the chief executive officer directly owned 404,318 shares of the company's stock, valued at approximately $5,506,811.16. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jacquelyn L. Sumer sold 3,742 shares of the company's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $13.62, for a total transaction of $50,966.04. Following the completion of the transaction, the insider directly owned 131,690 shares in the company, valued at $1,793,617.80. This trade represents a 2.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 78,492 shares of company stock valued at $1,113,359 in the last three months. Company insiders own 6.07% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Cullinan Therapeutics by 62.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company's stock worth $28,000 after buying an additional 1,036 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Cullinan Therapeutics during the 4th quarter valued at about $31,000. CWM LLC increased its holdings in shares of Cullinan Therapeutics by 51.5% during the 4th quarter. CWM LLC now owns 3,876 shares of the company's stock valued at $40,000 after acquiring an additional 1,318 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Cullinan Therapeutics by 689.7% during the 4th quarter. Signaturefd LLC now owns 4,130 shares of the company's stock valued at $43,000 after acquiring an additional 3,607 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Cullinan Therapeutics by 44.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock valued at $62,000 after acquiring an additional 2,523 shares during the last quarter. Institutional investors own 86.31% of the company's stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.